Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Código QR

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization

Abstract The authors performed a retrospective and comparative study to compare the efficacy of intravitreal aflibercept and bevacizumab for patients with myopic choroidal neovascularization (mCNV). The patients with treatment-naïve mCNV received 1 + PRN intravitreal bevacizumab from March 2008 to F...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jia-Kang Wang, Tzu-Lun Huang, Pei-Yao Chang, Yen-Ting Chen, Chin-Wei Chang, Fang-Ting Chen, Yung-Ray Hsu, Yun-Ju Chen
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Intravitreal Aflibercept Choroidal Neovascularization Best-corrected Visual Acuity (BCVA) Mean BCVA Aflibercept Group Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b1a16bb2849342a8b7df552ffc71a5b3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
por: Korol AR, et al.
Publicado: (2017)

Intravitreal aflibercept for the treatment of choroidal neovascularization associated with pathologic myopia: a pilot study
por: Korol AR, et al.
Publicado: (2016)

Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age
por: Karagiannis D, et al.
Publicado: (2017)

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
por: Balaratnasingam C, et al.
Publicado: (2015)

Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea
por: Ryu G, et al.
Publicado: (2021)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
por: Hirakata T, et al.
Publicado: (2016)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda SM, et al.
Publicado: (2017)

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
por: Patel PJ, et al.
Publicado: (2017)

Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
por: Arakawa A, et al.
Publicado: (2017)

Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
por: Elfandi S, et al.
Publicado: (2021)

Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study
por: Chen YX, et al.
Publicado: (2020)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
por: Khanani AM, et al.
Publicado: (2019)

Real-World Anti-Vascular Endothelial Growth Factor Therapy Outcomes in Myopic Choroidal Neovascularization
por: Bhatia D, et al.
Publicado: (2021)

Vitreous Reflux Frequency and Intraocular Pressure After First-Time Intravitreal Aflibercept Injections: Comparison of 30- and 32-Gauge Needles
por: Muto T, et al.
Publicado: (2020)

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study
por: Sakamoto S, et al.
Publicado: (2018)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019)

Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema
por: Dweikat A, et al.
Publicado: (2021)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
por: Azuma K, et al.
Publicado: (2018)

Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
por: Cui C, et al.
Publicado: (2017)

Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study
por: Kern C, et al.
Publicado: (2020)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
por: Xiu-Xian Wang, et al.
Publicado: (2021)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa B, et al.
Publicado: (2021)

Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials
por: Dugel PU, et al.
Publicado: (2016)

Clinical Outcome and Drug Expenses of Intravitreal Therapy for Diabetic Macular Edema: A Retrospective Study in Sardinia, Italy
por: Chiara Altana, et al.
Publicado: (2021)

Pachychoroid neovasculopathy in extramacular choroidal neovascularization
por: Gupta MP, et al.
Publicado: (2016)

Biomarkers of Myopic Choroidal Neovascularization in Women, Determining the Clinical Course and Response to Anti-VEGF Therapy
por: A. V. Grigorieva, et al.
Publicado: (2021)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2017)

The 2-Year Leakage Index and Quantitative Microaneurysm Results of the RECOVERY Study: Quantitative Ultra-Widefield Findings in Proliferative Diabetic Retinopathy Treated with Intravitreal Aflibercept
por: Amy S. Babiuch, et al.
Publicado: (2021)

Impact of Different Clinical Baseline Characteristics on Intravitreal Dexamethasone Implant Ozurdex® Outcomes
por: Udaondo P, et al.
Publicado: (2021)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)

Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice
por: Campos Polo R, et al.
Publicado: (2018)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2018)

Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization
por: Tan CS, et al.
Publicado: (2017)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose R, et al.
Publicado: (2016)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
por: Tran THC, et al.
Publicado: (2021)

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
por: Spooner K, et al.
Publicado: (2017)

Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept
por: Mansour AM, et al.
Publicado: (2019)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
por: Sakanishi Y, et al.
Publicado: (2017)

Idiopathic polypoidal choroidal vasculopathy in Thai patients with clinical and angiographic choroidal neovascularization
por: Bhoomibunchoo C, et al.
Publicado: (2017)

Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
por: Jang K, et al.
Publicado: (2020)